Introduction {#s1}
============

Several studies have demonstrated a decrease in Vitamin D receptor (VDR) expression in breast cancer cells compared to normal breast cells [@pone.0057967-Lopes1]. Decreased levels of VDR in breast cancer cells could be due to VDR gene polymorphisms [@pone.0057967-Engel1], and/or DNA methylation [@pone.0057967-Marik1]--[@pone.0057967-Banwell1]. Alterations in VDR expression and activity could lead to deregulation of Vitamin D uptake, metabolism, and serum levels of biologically active Vitamin D.

VDR gene has multiple gene polymorphisms [@pone.0057967-Nejentsev1], and four important single nucleotide polymorphisms (SNPs) in exon 2 and 3′UTR region. These are VDR-FokI (rs2228570), VDR-BsmI (rs1544410), VDR-TaqI (rs731236) and VDR-ApaI (rs7975232). Functional studies have identified that the VDR-FokI polymorphism leads to a shorter VDR protein by altering a translation initiation site [@pone.0057967-Alimirah1], [@pone.0057967-Jurutka1]. Large meta-analyses have demonstrated a significant association of the VDR FokI polymorphisms with breast cancer [@pone.0057967-Raimondi1], [@pone.0057967-Tang1], and other cancers across multiple ethnic cohorts [@pone.0057967-Mishra1], [@pone.0057967-Xu1]. The functional role of VDR-BSMI, VDR-TaqI, and VDR-ApaI, which are all located near the 3′UTR region, are not as clear. However, studies do suggest that these polymorphisms may alter the polyadenylation of the VDR mRNA transcript, and thus affect mRNA stability [@pone.0057967-Uitterlinden1]. Several studies show contradictory results on these polymorphisms and risk for breast cancer. Some studies found an association of breast cancer with BsmI, TaqI and ApaI [@pone.0057967-Ingles1]--[@pone.0057967-Yao1] polymorphisms while others found no associations [@pone.0057967-Rollison1]--[@pone.0057967-Trabert1].

We have examined four VDR polymorphisms (FokI, TaqI, BsmI, ApaI) in African-American and Hispanic women from South Los Angeles and their association with breast cancer risk and survival.

Materials and Methods {#s2}
=====================

Ethics Statement {#s2a}
----------------

This study, including the consent protocol, was approved by the Charles R. Drew University of Science and Medicine Institutional Review Board (Approval \# 00-06-041-13). Written informed consent was obtained from all participants.

Study Population {#s2b}
----------------

This is a retrospective cohort hospital-based study. Subjects were selected from our current breast study database in the Division of Cancer Research and Training, at Charles R. Drew University of Medicine and Science. We selected 232 women with breast cancer as Cases (115 African-Americans and 117 Hispanic/Latinas), and 349 normal, healthy women as Controls (73 African-Americans and 276 Latinas). Subjects were recruited between 1995 and 2007, and had documented personal history, clinical history, and tumor pathology data.

VDR polymorphisms {#s2c}
-----------------

Genomic DNA was extracted from buffy coat samples using the Qiagen DNA extraction kit. Vitamin D receptor genotyping for all four single-nucleotide polymorphic sites (SNPs) was done by the PCR-RFLP method (polymerase chain reaction- restriction fragment length polymorphism analysis). We used the following flanking primers [@pone.0057967-Curran1], [@pone.0057967-Trabert1]. The BsmI polymorphism was detected using one primer originating in exon 7 (Forward: 5′-CAACCAAGACTACAAGTACCGCGTCAGTGA-3′) and a second in intron 8 (Reverse: 5′-AACCAGCGGAAGAGGTCAAGGG-3′), amplifying an 823 base pair (bp) fragment spanning the BsmI site. The ApaI and TaqI polymorphisms were detected using one primer in intron 8 (Forward: 5′- AGAGCATGGACAGGGAGCAAG- 3′) and the other in exon 9 (Reverse: 5′-GCAACTCCTCATGGCTGAGGTCTCA- 3′), yielding a 745 bp fragment spanning the ApaI and TaqI site. VDR-FokI polymorphic site was amplified using following primers Forward -5′GATGCCAGCTGGCCCTGGCACTG3′ and Reverse -- 5′ATGGAAACACCTTGCTTCTTCTCCCTC 3′. PCR conditions were as follows: denaturation at 94°C for 5 min, followed by 40 cycles of PCR at 94°C (30 sec), 60°C--63.5°C (30 sec), and 72°C (30 sec). Annealing temperature for BsmI, ApaI/TaqI and FokI PCR are 63.5°C, 61°C and 59.5°C, respectively. Following PCR, aliquots of the amplified PCR products was digested with BsmI, ApaI, TaqI and FokI in accordance with the manufacturer\'s specifications (New England Biolabs, Beverly, MA, USA). The presence (lowercase) or absence (uppercase) of the enzyme recognition site was identified by ethidium bromide staining of fragments separated in a 2% agarose gel. Genotypes were assigned as BB, Bb, bb for the BsmI polymorphisms, AA, Aa, aa for the ApaI polymorphisms, TT, Tt and tt for the TaqI polymorphisms and FF, Ff and ff for the VDR-FokI polymorphisms. For the BsmI cleaved PCR products, the single resultant fragment was 823 bp, whereas the two resultant fragments were 648 bp and 175 bp. The PCR products digested with TaqI enzyme resulted in fragments of 496 bp and 249 bp in the presence of the polymorphic cutting site. PCR products digested with ApaI enzyme result in fragments of 531 bp and 214 bp in the presence of the polymorphic cutting site. The PCR products of VDR-FokI polymorphism (273 bp) digested with FokI enzyme result in 198 bp and 75 bp products in the presence of restriction site.

Statistical Analysis {#s2d}
--------------------

We used SPSS (ver 11.5) software to analyze our data. The Pearson Chi-square test was used to determine the statistically significant differences in frequency distribution of VDR genotypes between Cases and Controls. If the Table had cells with a frequency less than 5, Fisher\'s exact test was utilized. The 2-sided exact p-value\<0.05 was considered statistically significant. The deviation of distribution of VDR genotypes from Hardy-Weinberg equilibrium (HWE) was estimated using the web tool HWE Testing calculator, available online [@pone.0057967-Rodriquez1]. Associations between each VDR polymorphism and breast cancer was estimated using the Logistic Regression test at 95% confidence interval, and controlled for age and BMI. For each polymorphic site, the wild type genotype (FF, BB, AA, TT) was considered as the reference based on published literature. We also performed analysis of linkage disequilibrium (LD) between polymorphic sites in a locus, to identify "clusters" of highly correlated sites based on LD statistics. We calculated the haplotype frequencies and LD in Cases and Controls using the Haplotype software package available online [@pone.0057967-Barrett1], [@pone.0057967-Broad1].

Results {#s3}
=======

[Table 1](#pone-0057967-t001){ref-type="table"} shows the characteristics of subjects in the study. The mean age of African-American Cases and Controls is 52.9 and 50.7 years, respectively, and for Hispanic/Latinas Cases and Controls is 49.2 and 45.6 years, respectively. The mean BMI is \>30 kg/m∧2. Among Cases, the distribution of histopathological characteristics between African-American and Hispanic women with breast cancer was similar ([Table 1](#pone-0057967-t001){ref-type="table"}), and approximately ∼59.9% Cases had Stage I/II disease and 26.7% had Stage III/V disease. The majority of our patients had infiltrating ductal carcinoma (62.2%), moderately to poorly differentiated (\>70%).

10.1371/journal.pone.0057967.t001

###### Characteristics of Breast Cancer Cases and Controls.
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  Subject Characteristics                         African-American    Latina     *P*-Value[\*](#nt101){ref-type="table-fn"}
  ---------------------------------------------- ------------------ ----------- --------------------------------------------
  **Mean Age±SD (Range)**                                                       
  Cases                                                 53±9           49±11                       0.006
  Controls                                             51±10           46±10                       0.001
  *P*-Value[\*\*](#nt102){ref-type="table-fn"}          0.13           0.003    
  **Mean BMI±SD (Range)**                                                       
  Cases                                                 34±9           32±7                         0.01
  Controls                                              35±8           31±6                       \<0.001
  *P*-Value[\*\*](#nt102){ref-type="table-fn"}          0.74           0.19     
  **Cases Only (N = 232)**                           **N (%)**       **N (%)**  
  ***ER/PR Status***                                                            
  ER/PR+                                              60 (52)         54 (46)                       0.24
  ER/PR-                                              42 (37)         43 (37)   
  Unknown                                             13 (11)         20 (17)   
  ***HER2 Status***                                                             
  3+                                                  16 (14)         22 (19)                       0.64
  2+                                                  12 (10)         14 (12)   
  1+                                                  27 (24)         21 (18)   
  Negative                                            40 (35)         35 (30)   
  Unknown                                             20 (17)         25 (21)   
  **Histology**                                                                 
  Infiltrating Ductal Carcinoma                       72 (63)         72 (62)                       0.77
  Infiltrating Lobular Carcinoma                      20 (17)         15 (13)   
  Infiltrating Adenocarcinoma                          4 (4)           2 (2)    
  Infiltrating Intraductal Carcinoma                   0 (0)           1 (1)    
  Ductal                                               0 (0)           1 (1)    
  Lobular                                              2 (2)           2 (2)    
  Unknown                                             17 (15)         24 (2)    
  **Differentiation**                                                           
  Well                                                 10 (9)          6 (5)                        0.23
  Moderately                                          33 (29)         30 (26)   
  Poorly                                              55 (48)         55 (47)   
  Unknown                                             17 (15)         26 (22)   
  **Stage**                                                                     
  0                                                    7 (6)           8 (7)                        0.05
  I                                                   23 (20)          8 (7)    
  II                                                  46 (40)         47 (40)   
  III                                                 22 (19)         29 (25)   
  IV                                                   4 (4)           7 (6)    
  Unknown                                             13 (11)         18 (15)   

P-value\<0.05 is significant.

P-value assesses significance within the column. (P\<0.05 is significant).

The VDR gene polymorphisms were genotyped in 188 African-American and 393 Hispanics/Latina women. No deviation was observed from Hardy-Weinberg equilibrium (HWE) in the genotypic distribution of the VDR-FokI, VDR-BsmI and VDR-ApaI polymorphisms in the study subjects. However, the VDR-TaqI distribution was not within HWE. Further analysis identified that the deviation of VDR-TaqI was contributed from Cases (p allele = 0.75, q allele = 0.25, χ^2^ = 13.52), but not from Controls (p allele = 0.79, q allele = 0.21, χ^2^ = 2.34) -- data not shown.

Logistic regression analysis was also performed (adjusted for age and BMI) and showed no significant association of breast cancer with any of the VDR polymorphisms when all of the Cases were pooled together ([Table 2](#pone-0057967-t002){ref-type="table"}). However, when the analysis was performed based on ethnic stratification of the African-American and Hispanic/Latina subjects, the VDR-FokI *Ff* genotype (OR = 2.2, 95% CI = 0.95-5.1, p = 0.06) and the *f* allele (OR = 1.9, 95% CI = 0.9-3.7, p = 0.07) showed an increased association with breast cancer among African-American subjects ([Table 2](#pone-0057967-t002){ref-type="table"}) compared with the Hispanic/Latina subjects. In the Hispanic/Latina population, we found no significant difference in the frequency distribution of the VDR genotypes between Cases and Controls, and no association with any of the genotypes with breast cancer based on logistic regression analysis ([Table 2](#pone-0057967-t002){ref-type="table"}).

10.1371/journal.pone.0057967.t002

###### Distribution of VDR-FokI, VDR-BsmI, VDR-TaqI and VDR-ApaI genotypes in African-American and Hispanic/Latina Cases and Controls.
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                  All Subjects[†](#nt105){ref-type="table-fn"}   African-American Subjects[††](#nt106){ref-type="table-fn"}   Hispanic/Latina Subjects[††](#nt106){ref-type="table-fn"}                                                                                                
  -------------- ---------------------------------------------- ------------------------------------------------------------ ----------------------------------------------------------- ------ ---------- ---------- ----------------- ------ ---------- ---------- ----------------- ------
  **VDR-FokI**                                                                                                                                                                                                                                                                         
  FF                                148 (42)                                              95 (41)                                                        1.0                                     38 (52)    53 (46)          1.0                110 (40)   42 (36)          1.0        
  Ff                                144 (41)                                              110 (47)                                                 1.3 (0.8--2.1)                         0.26   30 (41)    55 (48)    2.2 (0.95--5.1)   0.06   114 (41)   55 (47)    1.0 (0.5--1.8)    0.98
  ff                                57 (16)                                               27 (12)                                                  1.3 (0.7--2.6)                         0.43    5 (7)      7 (6)     2.9 (0.3--26.3)   0.33   52 (19)    20 (17)    1.0 (0.5--2.2)    0.91
  F allele                          440 (63)                                              300 (64)                                                       1.0                                     106 (73)   161 (70)         1.0                334 (61)   139 (59)         1.0        
  f allele                          258 (37)                                              164 (35)                                                 1.2 (0.9--1.7)                         0.29   40 (27)    69 (30)    1.9 (0.9--3.7)    0.07   218 (40)   95 (41)    1.0 (0.7--1.5)    0.92
  **VDR-BsmI**                                                                                                                                                                                                                                                                         
  BB                                 26 (7)                                                19 (8)                                                        1.0                                      8 (11)     9 (8)           1.0                 18 (7)     10 (9)          1.0        
  Bb                                141 (40)                                              90 (39)                                                  0.8 (0.3--1.9)                         0.57   31 (43)    40 (35)    0.7 (0.1--3.6)    0.63   110 (40)   50 (43)    0.9 (0.3--2.4)    0.76
  bb                                182 (52)                                              123 (53)                                                 0.9 (0.3--1.9)                         0.59   34 (47)    66 (57)    1.4 (0.3--7.9)    0.68   148 (54)   57 (49)    0.6 (0.2--1.7)    0.34
  B allele                          193 (28)                                              128 (28)                                                       1.0                                     47 (32)    58 (25)          1.0                146 (26)   70 (30)          1.0        
  b allele                          505 (72)                                              336 (72)                                                 0.9 (0.7--1.3)                         0.76   99 (68)    172 (75)   1.6 (0.9--2.9)    0.15   406 (74)   164 (70)   0.75 (0.5--1.1)   0.19
  **VDR-TaqI**                                                                                                                                                                                                                                                                         
  TT                                223 (64)                                              141 (61)                                                       1.0                                     40 (55)    66 (57)          1.0                183 (66)   75 (64)          1.0        
  Tt                                106 (30)                                              66 (28)                                                  0.8 (0.5--1.3)                         0.31   28 (38)    35 (30)    0.6 (0.3--1.4)    0.24   78 (28)    31 (27)    0.9 (0.5--1.6)    0.66
  tt                                 20 (6)                                               25 (11)                                                  1.3 (0.5--3.0)                         0.58    5 (7)     14 (12)    1.1 (0.3--4.4)    0.91    15 (5)     11 (9)    1.4 (0.5--4.0)    0.59
  T allele                          552 (79)                                              348 (75)                                                       1.0                                     108 (74)   167 (73)         1.0                444 (80)   181 (77)         1.0        
  t allele                          146 (21)                                              116 (25)                                                 0.9 (0.7--1.4)                         0.85   38 (26)    63 (27)    0.8 (0.5--1.6)    0.60   108 (20)   53 (23)    1.0 (0.6--1.6)    0.91
  **VDR-ApaI**                                                                                                                                                                                                                                                                         
  AA                                110 (32)                                              82 (35)                                                        1.0                                     28 (38)    49 (43)          1.0                82 (29)    33 (28)          1.0        
  Aa                                185 (53)                                              115 (50)                                                 1.0 (0.6--1.7)                         0.88   33 (45)    54 (47)    0.8 (0.3--1.8)    0.51   152 (55)   61 (52)    1.3 (0.7--2.4)    0.49
  aa                                54 (16)                                               35 (15)                                                  1.1 (0.5--2.1)                         0.88   12 (16)    12 (10)    0.6 (0.2--2.2)    0.45   42 (15)    23 (20)    1.3 (0.6--3.0)    0.47
  A allele                          405 (58)                                              279 (60)                                                       1.0                                     89 (61)    152 (66)         1.0                316 (57)   127 (54)         1.0        
  a allele                          293 (42)                                              185 (40)                                                 1.0 (0.7--1.4)                         0.88   57 (39)    78 (34)    0.8 (0.4--1.4)    0.42   236 (43)   107 (46)   1.2 (0.8--1.7)    0.47

Note: For analysis of alleles F and f, B and b, T and t, A and a, each subject was used twice. **F**- wild type FokI, **f**- polymorphic FokI; **B**- wild type BsmI, **b**-polymorphic BsmI; **T**- wild type TaqI, **t**- polymorphic TaqI; **A**- wild type ApaI, **a**- polymorphic ApaI.

P-value is significant if P\<0.05;

Analysis adjusted for age, BMI and ethnicity;

Analysis adjusted for age and BMI.

Haplotype analysis of the polymorphic variants produced 16 different haplotypes ([Table 3](#pone-0057967-t003){ref-type="table"}). The FBTA (*FokI-F, BsmI-B, TaqI-T and ApaI-A*) was the most common haplotype in Controls and Hispanic/Latina Cases ([Table 3](#pone-0057967-t003){ref-type="table"}). The most common haplotype in African-American Cases was the FbTA haplotype (*FokI-F, BsmI-b, TaqI-T and ApaI-A*). Several VDR-haplotypes were significantly associated with breast cancer in the African-American cohort, however, no association was observed between breast cancer and VDR-haplotypes in the Hispanic/Latina cohort. Logistic regression analysis, using wild-type alleles (FBTA) as the reference category, revealed that FbTA was 1.9 times higher (p = 0.02), FbtA was 1.6 times higher (p = 0.03) and fbtA was 1.4 times higher (p = 0.05) in Cases than in Controls in the African-American cohort ([Table 3](#pone-0057967-t003){ref-type="table"}). Logistic regression analysis performed in Cases showed that African-American women with breast cancer were more likely to have the FbTA (OR = 2.4, p = 0.005) and FbtA (OR = 1.7, p = 0.04) haplotypes compared with Hispanic/Latina women with breast cancer. In contrast to Cases, African-American Controls with the fbTa (OR = 0.8, p\<0.001), fbTA (OR = 0.8, p = 0.03), fBTA (OR = 0.8, p = 0.04) and fbtA (OR = 0.7, p = 0.02) haplotypes were significantly less frequently observed than among Hispanic/Latina Controls.

10.1371/journal.pone.0057967.t003

###### VDR haplotypes, Breast Cancer, and Ethnicity.
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  *Association of VDR haplotypes and breast cancer in African-American and Hispanic/Latina women*                                                                
  ------------------------------------------------------------------------------------------------- ------ ------ ------ ------------------------- ------ ------ ---------------------
  FBTA                                                                                               TGTC   17.0   25.4              1              19.5   16.7            1
  FbTA                                                                                               TATC   26.3   20.6   **1.9 (1.1--3.3) 0.02**   12.4   15.6   0.7 (0.4--1.2) 0.20
  FbTa                                                                                               TATA   7.1    13.4     0.9 (0.8--1.1) 0.53     14.6   11.4   1.0 (0.9--1.1) 0.76
  fbTa                                                                                               CATA   12.1   5.8     1.1 (1.0--1.2) 0.002     16.8   16.4   0.9 (0.9--1.0) 0.65
  fbTA                                                                                               CATC   5.8    5.2      1.1 (0.9--1.4) 0.22     8.0    7.4    0.9 (0.8--1.2) 0.82
  FbtA                                                                                               TACC   7.6    4.5    **1.6 (1.1--2.4) 0.03**   3.1    2.9    0.9 (0.6--1.6) 0.86
  FBTa                                                                                               TGTA   1.8    2.1      1.0 (0.9--1.2) 0.70     2.2    2.7    0.9 (0.8--1.1) 0.57
  fBTA                                                                                               CGTC   1.8    2.1      1.0 (0.8--1.2) 0.70     2.2    4.0    0.9 (0.8--1.1) 0.18
  fBTa                                                                                               CGTA   0.9    0.7      1.0 (0.9--1.2) 0.51     0.9    1.6    0.9 (0.8--1.1) 0.38
  fbtA                                                                                               CACC   4.5    2.4    **1.4 (1.1--1.9) 0.05**   5.8    4.8    1.0 (0.8--1.3) 0.94
  FBtA                                                                                               TGCC   3.1    4.8      1.0 (0.8--1.2) 0.96     3.1    2.9    0.9 (0.8--1.2) 0.86
  Fbta                                                                                               TACA   6.3    4.8      1.1 (0.9--1.1) 0.12     3.1    4.8    0.9 (0.8--1.0) 0.23
  fBta                                                                                               CGCA   0.0    1.7              \-              0.9    0.3    1.1 (0.9--1.3) 0.40
  fBtA                                                                                               CGCC   0.0    1.7              \-              0.4    1.1    0.8 (0.7--1.2) 0.37
  FBta                                                                                               TGCA   0.4    0.0              \-              1.3    0.0            \-
  fbta                                                                                               CACA   5.4    4.8      1.0 (0.9--1.1) 0.25     5.8    7.4    0.9 (0.9--1.0) 0.29

  *Association of VDR haplotypes and ethnicity in Cases and Controls*                                                                 
  --------------------------------------------------------------------- ------ ------ ------ -------------------------- ------ ------ ----------------------------
  FBTA                                                                   TGTC   17.0   19.5              1               25.4   16.7               1
  FbTA                                                                   TATC   26.3   12.4   **2.4 (1.3--4.6) 0.005**   20.6   15.6      0.9 (0.5--1.4) 0.87
  FbTa                                                                   TATA   7.1    14.6     0.9 (0.8--1.0) 0.13      13.4   11.4      1.0 (0.9--1.1) 0.36
  fbTa                                                                   CATA   12.1   16.8     1.0 (0.9--1.1) 0.56      5.8    16.4   **0.8 (0.8--0.9) \<0.001**
  fbTA                                                                   CATC   5.8    8.0      1.0 (0.8--1.2) 0.68      5.2    7.4     **0.8 (0.7--0.9) 0.03**
  FbtA                                                                   TACC   7.6    3.1    **1.7 (1.0--2.7) 0.04**    4.5    2.9       1.0 (0.6--1.6) 0.99
  FBTa                                                                   TGTA   1.8    2.2      1.0 (0.9--1.1) 0.91      2.1    2.7       0.9 (0.8--1.0) 0.22
  fBTA                                                                   CGTC   1.8    2.2      1.0 (0.8--1.2) 0.91      2\.    4.0     **0.8 (0.7--1.0) 0.04**
  fBTa                                                                   CGTA   0.9    0.9      1.0 (0.9--1.2) 0.87      0.7    1.6       0.9 (0.8--1.0) 0.13
  fbtA                                                                   CACC   4.5    5.8      1.0 (0.7--1.3) 0.81      2.4    4.8     **0.7 (0.6--0.9) 0.02**
  FBtA                                                                   TGCC   3.1    3.1      1.0 (0.8--1.2) 0.80      4.8    2.9       1.0 (0.9--1.2) 0.86
  Fbta                                                                   TACA   6.3    3.1      1.1 (0.9--1.2) 0.10      4.8    4.8       1.0 (0.9--1.0) 0.30
  fBta                                                                   CGCA   0.0    0.9               \-              1.7    0.3       1.1 (0.9--1.4) 0.19
  fBtA                                                                   CGCC   0.0    0.4               \-              1.7    1.1       1.0 (0.9--1.2) 0.93
  FBta                                                                   TGCA   0.4    1.3      0.9 (0.8--1.1) 0.42       \-     \-                \-
  fbta                                                                   CACA   5.4    5.8      1.0 (0.9--1.1) 0.88      4.8    7.4     **0.9 (0.9--0.99) 0.02**

Cases vs. Controls, Significance is P\<0.05;

African-American vs. Hispanic/Latina ethnicity, Significance is P\<0.05.

[Table 4](#pone-0057967-t004){ref-type="table"} demonstrates the results from linkage disequilibrium (LD) analysis performed on the four VDR variants. The strongest LD is observed between *VDR-TaqI* and *VDR-ApaI* among Hispanic/Latina subjects (D′ = 0.66). Weaker LDs were observed between *VDR-FokI* and the other 3 variants (*VDR-BsmI*, *VDR-ApaI* and, *VDR-TaqI*) in both African-American and Hispanic/Latinas.

10.1371/journal.pone.0057967.t004

###### Linkage disequilibrium (LD) between VDR polymorphisms in African-American and Hispanic/Latina women.
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                      Locus 1   Locus 2          D′ (CI)          LOD    r^2^
  ------------------ --------- --------- ----------------------- ------ -------
  African-American     VDRF      VDRB       0.09 (0.00--0.04)     0.06   0.001
                       VDRF      VDRA       0.14 (0.02--0.29)     0.56   0.01
                       VDRF      VDRT       0.17 (0.00--0.44)     0.21   0.004
                       VDRB      VDRA       0.09 (0.00--0.37)     0.07   0.002
                       VDRB      VDRT       0.16 (0.03--0.28)     1.01   0.02
                       VDRA      VDRT       0.32 (0.07--0.53)     0.94   0.02
  Hispanic/Latina      VDRF      VDRB       0.12 (0.00--0.30)     0.27   0.003
                       VDRF      VDRA       0.08 (0.00--0.18)     0.58   0.006
                       VDRF      VDRT       0.14 (0.01--0.30)     0.30   0.003
                       VDRB      VDRA       0.25 (0.08--0.40)     1.48   0.02
                       VDRB      VDRT       0.38 (0.27--0.48)     7.80   0.10
                       VDRA      VDRT     **0.66 (0.49--0.77)**   8.44   0.09

Note: All samples were in Hardy-Weinberg Equilibrium (HWE) among the groups. LD was calculated between markers among African-Americans or Hispanics/Latinas. D′ is the prime between the loci; LOD is the log of likelihood odds ratio, a measure of confidence in the D\'value; r^2^ is the correlation coefficient between the two loci.

The associations between the VDR genotypes and breast tumor histopathology, tumor stage, and metastatic disease progression were assessed in [Table 5](#pone-0057967-t005){ref-type="table"}. The VDR-FokI *FF* genotype was significantly more common in African-American patients than in Hispanic/Latina patients (46.1% vs. 35.9%, respectively, p = 0.02), while the VDR-FokI *ff* genotype was more common in Hispanic/Latina patients as compared to African-American patients (17.1% vs. 6.1%, respectively). African-American patients were more likely to have VDR-ApaI *AA* genotype and Hispanic/Latina patients were likely to have VDR-ApaI *Aa* or *aa* genotypes (p = 0.008). There was also a significant association identified between VDR-ApaI polymorphisms and tumor differentiation (p = 0.04). Poorly differentiated tumors were more likely to express a polymorphic allele of VDR-ApaI (*Aa* or *aa*). There were no other significant associations found between any of the polymorphic VDR variants and tumor stage, tumor differentiation, and ER/PR/HER2 receptor status.

10.1371/journal.pone.0057967.t005

###### Association of VDR genotypes with Tumor Pathology and Ethnicity.

![](pone.0057967.t005){#pone-0057967-t005-5}

                              VDR-FokI     VDR-BsmI   VDR-TaqI     VDR-ApaI                                               
  ------------------------ -------------- ---------- ---------- --------------- ----- ----- ----- ----- ----- ----- ----- -----
  **Ethnicity**                                                                                                           
  AA                            46%          48%         6%           8%         35%   57%   57%   30%   12%   43%   47%   10%
  Latina                        36%          47%        17%           9%         43%   49%   64%   27%   9%    28%   52%   20%
                            **p = 0.02**   p = n.s.   p = n.s.   **p = 0.008**                                            
  **ER/PR Status**                                                                                                        
  ER/PR+ve                      42%          47%        11%           8%         41%   51%   59%   29%   12%   36%   49%   15%
  ER/PR -ve                     42%          46%        12%           6%         39%   55%   62%   25%   13%   35%   51%   14%
                              p = n.s.     p = n.s.   p = n.s.     p = n.s.                                               
  **HER2 Status**                                                                                                         
  HER2 +ve                      40%          55%         5%           11%        40%   50%   63%   21%   16%   42%   45%   13%
  HER2 -ve                      42%          45%        13%           7%         40%   54%   60%   28%   11%   36%   52%   12%
                              p = n.s.     p = n.s.   p = n.s.     p = n.s.                                               
  **Distant Metastasis**                                                                                                  
  Yes                           44%          56%         0%           11%        33%   56%   56%   22%   22%   33%   33%   33%
  No                            41%          47%        12%           7%         40%   53%   61%   28%   11%   37%   48%   15%
                              p = n.s.     p = n.s.   p = n.s.     p = n.s.                                               
  **Differentiation**                                                                                                     
  Well                          44%          33%        22%           0%         44%   56%   56%   44%   0%    67%   33%   0%
  Moderate                      34%          51%        15%           7%         53%   41%   59%   31%   10%   33%   61%   7%
  Poor                          44%          47%         9%           8%         38%   55%   61%   24%   16%   34%   46%   20%
                              p = n.s.     p = n.s.   p = n.s.   **p = 0.04**                                             
  **Stage**                                                                                                               
  0                             53%          33%        13%           13%        27%   60%   60%   40%   0%    40%   27%   33%
  Ι                             39%          48%        13%           10%        32%   58%   55%   36%   10%   32%   48%   19%
  ΙΙ                            39%          50%        12%           5%         42%   53%   63%   24%   13%   41%   47%   12%
  ΙΙΙ                           46%          47%         8%           6%         43%   51%   65%   24%   12%   31%   55%   14%
  ΙV                            36%          46%        18%           9%         36%   55%   46%   27%   27%   36%   36%   27%
                              p = n.s.     p = n.s.   p = n.s.     p = n.s.                                               

Note: N.s. is not-significant with a P-value\>0.05. Significance is P\<0.05.

The 5-year disease-free-survival (DFS) from breast cancer in association with VDR polymorphisms is shown in [Figure 1](#pone-0057967-g001){ref-type="fig"}. The 5-year DFS in patients carrying VDR-FokI *FF* genotype is reduced significantly compared to VDR-FokI *Ff* and *ff* genotypes (p = 0.05). The VDR-BsmI, VDR-ApaI and VDR-TaqI polymorphisms did not influence DFS significantly. [Results](#s3){ref-type="sec"} of multivariate analyses, adjusted for the tumor characteristics, ethnicity, and the four VDR polymorphic variants, confirm the independent predictor value of VDR-FokI in DFS as shown in [Table 6](#pone-0057967-t006){ref-type="table"}. The relative risk of tumor recurrence or metastases was decreased by 43% in patients who had the polymorphic VDR-FokI alleles, *Ff* or *ff*, compared to subjects who had VDR-FokI *FF* genotype ([Table 6](#pone-0057967-t006){ref-type="table"}).

![Five-year disease free survival (DFS) of breast cancer patients in relation to VDR gene polymorphisms.\
Kaplan-Meier survival curves were used to compare the 5-year DFS between the VDR gene polymorphisms in (a) VDR-FokI, (b) VDR-BsmI, (c) VDR-ApaI, and (d) VDR-TaqI. The differences between the curves were estimated by log-rank test, where P\<0.05 was considered statistically significant.](pone.0057967.g001){#pone-0057967-g001}

10.1371/journal.pone.0057967.t006

###### Relative Risk of worse Disease-Free-Survival in relation to VDR gene polymorphisms (Multivariate Analysis).
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  Polymorphism    RR[\*](#nt111){ref-type="table-fn"}      (95% CI)      *P*-value
  -------------- ------------------------------------- ---------------- -----------
  **FokI**                                                              
  FF                             **1**                  **(0.3--0.9)**   **0.05**
  Ff+ff                        **0.57**                                 
  **BsmI**                                                              
  BB                               1                      (0.3--1.9)       0.45
  Bb+bb                          0.67                                   
  **ApaI**                                                              
  AA                               1                      (0.5--1.7)       0.80
  Aa+aa                          0.92                                   
  **TaqI**                                                              
  TT                               1                      (0.7--2.4)       0.48
  Tt+tt                           1.3                                   

RR: Relative Risk adjusted for tumor characteristics and ethnicity.

Discussion {#s4}
==========

The results from our study reveal an increased association between one of the VDR polymorphic variants, VDR-FokI, and breast cancer in the African-American cohort. The odds ratio (OR) for breast cancer in association with the VDR-FokI *f* allele was 1.9 (95% CI = 0.9--3.7; p = 0.07). This is consistent with other studies [@pone.0057967-McKay1] which have identified a positive association between the VDR-FokI *ff* genotype and/or *f* allele and breast cancer ([Table 7](#pone-0057967-t007){ref-type="table"}). Our study further identifies that this trend is present among African-American women, but not Hispanic/Latina women. The other most commonly studied VDR polymorphism, VDR-BsmI, was not associated with breast cancer in our study, similar to most of the other studies conducted on this polymorphism ([Table 7](#pone-0057967-t007){ref-type="table"}). While Ingles *et al* [@pone.0057967-Ingles1] identified a significant association of the *B* allele with breast cancer among Hispanics, recent large studies and meta-analyses on various ethnic groups, including Hispanics, have suggested otherwise. For example, the large analyses conducted by Rollison *et al* [@pone.0057967-Rollison1] and Tang *et al* [@pone.0057967-Tang1] have confirmed that there is no significant association between VDR-BsmI and breast cancer. Furthermore, data from our current study shows no associations between the two other VDR variants (TaqI and ApaI) and breast cancer, consistent with most studies to date on Caucasian populations ([Table 7](#pone-0057967-t007){ref-type="table"}). The VDR-TaqI (*tt* genotype) and VDR-ApaI (*a* allele) were significantly associated with breast cancer in only two hospital-based studies [@pone.0057967-McCullough1], [@pone.0057967-Curran1]. However, these polymorphisms were found to be non-significant in recent large population meta-analyses [@pone.0057967-Tang1]. Linkage-disequilibrium analysis of the polymorphisms in our study is also consistent with findings from previous studies, confirming linkage between VDR-TaqI and VDR-ApaI in Hispanic/Latina women, and absence of LD between the VDR-FokI and other SNPs [@pone.0057967-Nejentsev1].

10.1371/journal.pone.0057967.t007

###### Summary of Studies on Breast Cancer and VDR polymorphisms.
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  *Reference*                                                *Study design*         *Ethnicity*                 *No. of Cases*              *No. of Controls*   *Association between VDR polymorphism and breast cancer*                                                                                             
  ------------------------------------------------------- --------------------- -------------------- ------------------------------------- ------------------- ---------------------------------------------------------- --------------------------------------------- -------------------------------------------- ------------
  Curran, 1999 [@pone.0057967-Curran1]                          Hospital             Caucasian                        135                          110                                   *n.s.*                                                                                            *n.s.*                     *a allele*
  Dunning, 1999 [@pone.0057967-Dunning1]                   Hospital/Population       Caucasian                        951                          627                                                                                                                                     *n.s.*                    
  Ingles, 2000 [@pone.0057967-Ingles1]                         Population             Latinas                         143                          300                                   *n.s.*                                            *B allele*                                                                
  Bretherton-Watt, 2001 [@pone.0057967-BrethertonWatt1]         Hospital             Caucasian                        181                          241                                   *n.s.*                                             *bb type*                                                                
  Guy, 2004 [@pone.0057967-Guy1]                                Hospital             Caucasian                        398                          427                                   *n.s.*                                             *bb type*                                                                
  Hefler, 2004 [@pone.0057967-Hefler1]                     Hospital/Population       Caucasian                        390                         1,699                                                                                       *n.s*                                                                  
  Chen, 2005 [@pone.0057967-Chen1]                             Population            Caucasian                       1,234                        1,676                                *ff type*                                             *n.s.*                                                                  
  Vande Vord, 2006 [@pone.0057967-VandeVord1]                   Hospital               Mixed                          220                          192                                                                                       *n.s.*                                                                  
                                                                                 Caucasian (50.3%)                                                                                                                                                                                                                   
                                                                                     AA(49.7%)                                                                                                                                                                                                                       
  John, 2007 [@pone.0057967-John1]                             Population              Mixed                         1,786                        2,127                                  *n.s.*                                              *n.s.*                                        *n.s.*                    
                                                                                     Caucasian                        596                          646                                                                                                                                                               
                                                                                         AA                           543                          598                                                                                                                                                               
                                                                                      Hispanic                        647                          883                                                                                                                                                               
  McCullough, 2007 [@pone.0057967-McCullough1]                 Population            Caucasian                        500                          500                                   *n.s.*                                              *n.s.*                                        *n.s.*                       *n.s.*
  Trabert, 2007 [@pone.0057967-Trabert1]                       Population            Caucasian                       1,143                         987                                                                     *bb type* [\*](#nt113){ref-type="table-fn"}                                               
                                                                                         AA                           488                          448                                                                                       *n.s.*                                                                  
  Abbas, 2008 [@pone.0057967-Abbas1]                           Population            Caucasian                       1,403                        2,609                                  *n.s.*                                                                                            *n.s.*                    
  Gapska, 2008 [@pone.0057967-Gapska1]                         Population            Caucasian        800[∧](#nt114){ref-type="table-fn"}          550                                 *f allele*                                            *n.s.*                                        *n.s.*                    
  Sinotte, 2008 [@pone.0057967-Sinotte1]                   Hospital/Population       Caucasian                        859                         1,381                                *ff type*                                             *n.s.*                                                                  
  Barroso, 2008 [@pone.0057967-Barroso1]                        Hospital             Caucasian                        549                          556                *ff type* [\#](#nt115){ref-type="table-fn"}                                                        *tt type* [a](#nt116){ref-type="table-fn"}  
  McKay, 2009 [@pone.0057967-McKay1]                           Population            Caucasian                        378                          421                                   *n.s.*                                              *n.s.*                                                                  
                                                                                         AA                           325                          419                                   *n.s.*                                              *n.s.*                                                                  
                                                                                      Hispanic                        318                          378                                   *n.s.*                                              *n.s.*                                                                  
                                                                                       Asian                          401                          405                                 *ff type*                                          *Bb type^a^*                                                               
                                                                                      Hawaiian                        104                          278                                   *n.s.*                                              *n.s.*                                                                  
  Tang, 2009 [@pone.0057967-Tang1]                            Meta-Analysis       All ethnicities                   \>5,000                      \>7,000                               *ff type*                                             *n.s.*                                        *n.s.*                       *n.s.*
  Raimondi, 2009 [@pone.0057967-Raimondi1]                       Review           All ethnicities                   14,863                       21,318                                *ff type*                                             *n.s.*                                                                  
  Rollinson, 2012 [@pone.0057967-Rollison1]                    Population        Non-Hispanic White                  1,527                        1,599                                  *n.s*                                               *n.s.*                                                                  
                                                                                      Hispanic                        791                          922                                                                                                                                                               
  Vadgama, 2012                                                 Hospital                 AA                           115                          73                        *f vs. F, OR = 1.9, p = 0.07*                                   *n.s.*                                        *n.s.*                       *n.s.*
                                                                                       Latina                         117                          267                                   *n.s.*                                              *n.s.*                                        *n.s.*                       *n.s.*

AA: African-American.

for postmenopausal women.

for early-onset breast cancer (age\<50).

OR adjusted for age at diagnosis, number of live births, age at menarche and menopause.

associated with low risk of breast cancer.

Additional studies on VDR SNPs [@pone.0057967-Abbas1]--[@pone.0057967-Barroso1] are presented in [Table 7](#pone-0057967-t007){ref-type="table"}. Abbas *et al* [@pone.0057967-Abbas1], suggested that VDR polymorphisms may affect postmenopausal breast cancer risk, and be associated with receptor status. Our study shows no receptor-specific association (ER/PR/HER +/−) with any of the VDR polymorphic variants; however, the VDR-ApaI *aa* genotype is significantly associated with poorly differentiated tumors (p = 0.04). Since the VDR-ApaI *a* allele is most common in Hispanic/Latinas, and the Latinas in the present study were slightly younger than the African-American subjects, these findings may potentially implicate VDR-ApaI in the progression of cancer among younger breast cancer patients. Further investigation among larger numbers of younger women with breast cancer is necessary in order to discern a definite association.

Lastly, recent reviews have concluded that the scientific evidence between vitamin D status and breast cancer risk and outcome are fairly strong, and improving vitamin D levels could improve health status [@pone.0057967-Mohr1]. Unfortunately, studies to date which have utilized vitamin D supplementation to overcome vitamin D insufficiency have not yielded conclusive improvements in cancer health risks and outcomes [@pone.0057967-Chlebowski1], [@pone.0057967-Buttigliero1]. Hence examination of the Vitamin D receptor (VDR), and genetic changes such as polymorphisms potentially impacting VDR protein function may be central in identifying confounding factors that play a role in Vitamin D activity and ultimately patient outcome. Our study identifies that the 5-year disease-free-survival from breast cancer is significantly reduced among breast cancer patients with the VDR-FokI *FF* genotype (Log rank = 6.06 and p = 0.05). Cox regression with multivariate analysis demonstrates the independently predictive value of VDR-FokI on DFS. Hence, findings from our study suggest that while the VDR-FokI *f* allele may play a role in early association with breast cancer development, the *F* allele may play a role on tumor progression and patient outcome. The findings on these VDR variants, together with significant differences in haplotypes between Cases and Controls suggest the potential need to screen for VDR polymorphisms in the context of breast cancer, particularly before considering Vitamin D supplementation.
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